Details of Disease

General Information of Disease (ID: DIS9D5XU)

Disease Name Burkitt lymphoma
Synonyms
BL; Burkitt lymphoma; malignant lymphoma, Burkitt's type; Burkitt's tumor or lymphoma; Burkitt lymphoma/leukemia; small non-cleaved cell lymphoma, Burkitt's type; Burkitt's tumour; small non-cleaved cell lymphoma; Burkitt's lymphoma; burkitt lymphoma, somatic; Burkitt's tumor; Burkitt's tumour or lymphoma
Definition Burkitt lymphoma is a rare form of malignant mature B-cell non-Hodgkin lymphoma.
Disease Hierarchy
DISYKSRF: Genetic disease
DISD8DU7: Aggressive B-cell non-Hodgkin lymphoma
DISUUNPX: Epstein-Barr virus-associated malignant lymphoproliferative disorder
DISKAXO0: Neoplasm of mature B-cells
DIS9D5XU: Burkitt lymphoma
Disease Identifiers
MONDO ID
MONDO_0007243
MESH ID
D002051
UMLS CUI
C0006413
OMIM ID
113970
MedGen ID
2377
HPO ID
HP:0030080
Orphanet ID
543
SNOMED CT ID
118617000

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)
This Disease is Treated as An Indication in 4 Approved Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
Dexamethasone DMMWZET Approved Small molecular drug [1]
Doxorubicin DMVP5YE Approved Small molecular drug [2]
Methotrexate DM2TEOL Approved Small molecular drug [3]
Vincristine DMINOX3 Approved Small molecular drug [4]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)
This Disease Is Related to 79 DTT Molecule(s)
Gene Name DTT ID Evidence Level Mode of Inheritance REF
MYC TTZILNJ No Known Unknown [5]
AICDA TTKRTP6 Limited Biomarker [6]
BAX TTQ57WJ Limited Altered Expression [7]
CD38 TTPURFN Limited Biomarker [8]
CD40LG TTIJP3Q Limited Altered Expression [9]
MDM2 TT9TE0O Limited Biomarker [10]
PDGFRA TT8FYO9 Limited FusionGene [11]
SMARCA4 TTVQEZS Limited Altered Expression [12]
TCL1A TTUKRDV Limited Biomarker [13]
CD19 TTW640A Disputed Biomarker [14]
FLT3 TTGJCWZ moderate SomaticCausalMutation [15]
FOXP1 TT0MUCI moderate FusionGene [16]
GATA3 TT45KOB moderate SusceptibilityMutation [17]
RET TT4DXQT moderate Biomarker [18]
ABL2 TT1A6HL Strong Altered Expression [19]
APCS TTB7VAT Strong Altered Expression [20]
BBC3 TT7JUKC Strong Altered Expression [21]
BCL2L2 TTQ79W8 Strong Altered Expression [22]
CCND3 TT1JXNR Strong Genetic Variation [23]
CD22 TTM6QSK Strong Altered Expression [24]
CD40 TT1ERKL Strong Altered Expression [25]
CD6 TTMF6KC Strong Genetic Variation [26]
CD70 TTNCIE0 Strong Genetic Variation [27]
CD79B TTBN5I7 Strong Biomarker [28]
CDC25C TTESBNC Strong Altered Expression [29]
CDKN2A TTFTWQ8 Strong Genetic Variation [30]
CGB3 TTUH273 Strong Altered Expression [31]
CR2 TT0HUN7 Strong Altered Expression [32]
CSF3R TTC70AJ Strong Altered Expression [33]
DNMT3B TT6VZ78 Strong Biomarker [34]
DUSP5 TTZN92A Strong Genetic Variation [35]
DUT TTH6MBO Strong Biomarker [36]
ENTPD1 TTYM8DJ Strong Biomarker [37]
FCER2 TTCH6MU Strong Altered Expression [38]
GBA TT1B5PU Strong Biomarker [39]
GMNN TT390KA Strong Altered Expression [40]
HDAC7 TTMUEK1 Strong Biomarker [41]
IFNAR2 TTMQB37 Strong Biomarker [42]
IL12RB2 TT4SWR8 Strong Altered Expression [43]
IL13RA2 TTMPZ7V Strong Altered Expression [38]
IL18RAP TTZUJVE Strong Biomarker [44]
ITGAL TT48WR6 Strong Altered Expression [45]
LGALS1 TTO3NYT Strong Biomarker [29]
LMO2 TTFX379 Strong Biomarker [46]
LONP1 TTM1VPZ Strong Altered Expression [47]
MAPK10 TT056SO Strong Biomarker [48]
MAPK11 TT73U6C Strong Biomarker [49]
MASP2 TTR01E9 Strong Biomarker [50]
MCL1 TTL53M6 Strong Altered Expression [34]
MS4A1 TTUE541 Strong Altered Expression [51]
NAAA TTMN4HY Strong Biomarker [52]
NAGLU TTDM6HZ Strong Altered Expression [53]
NPR2 TTNB7IF Strong Biomarker [39]
NUAK1 TT65FL0 Strong Altered Expression [54]
P2RY8 TT84EWY Strong Genetic Variation [39]
PAX5 TTA4REJ Strong Biomarker [55]
PIM1 TTTN5QW Strong Altered Expression [47]
PIM3 TTCGOIN Strong Altered Expression [56]
PINX1 TT4FJ3A Strong Biomarker [57]
PLK2 TT976FS Strong Altered Expression [58]
PSMB6 TT8EPLT Strong Altered Expression [59]
PTPN6 TT369M5 Strong Biomarker [60]
RUNX1 TTWIN3H Strong Altered Expression [61]
SENP1 TTW9HY5 Strong Biomarker [62]
SIRPA TTBRJS9 Strong Altered Expression [51]
SYK TT2HUPM Strong Altered Expression [63]
TCF3 TTULOD8 Strong Biomarker [64]
TNFRSF13C TT7NJSE Strong Biomarker [57]
TNFRSF8 TT2GM5R Strong Altered Expression [65]
TNFSF13B TTWMIDN Strong Biomarker [66]
TPP2 TTQ7R2V Strong Altered Expression [67]
TSG101 TTHU7JA Strong Altered Expression [68]
TYRO3 TTIEMFN Strong Genetic Variation [69]
WDR5 TT7OFWB Strong Biomarker [70]
WWP2 TT6TU05 Strong Altered Expression [31]
ZAP70 TTUMHT8 Strong Altered Expression [71]
ABL1 TT6B75U Definitive Biomarker [72]
KMT2A TT1GNDM Definitive Genetic Variation [73]
RHOA TTP2U16 Definitive Genetic Variation [74]
------------------------------------------------------------------------------------
⏷ Show the Full List of 79 DTT(s)
This Disease Is Related to 1 DTP Molecule(s)
Gene Name DTP ID Evidence Level Mode of Inheritance REF
SLC25A20 DTQOUM4 Strong Genetic Variation [75]
------------------------------------------------------------------------------------
This Disease Is Related to 2 DME Molecule(s)
Gene Name DME ID Evidence Level Mode of Inheritance REF
DHRS9 DEGTU5I Limited Biomarker [76]
UCK2 DETN1O0 Strong Altered Expression [77]
------------------------------------------------------------------------------------
This Disease Is Related to 120 DOT Molecule(s)
Gene Name DOT ID Evidence Level Mode of Inheritance REF
MYC OTPV5LUK No Known Unknown [5]
BCL2L11 OTNQQWFJ Limited Altered Expression [78]
BCR OTCN76C1 Limited Biomarker [72]
FCRL5 OTA7VHNE Limited Altered Expression [79]
NAA15 OT53SIZG Limited Altered Expression [80]
TMEM132D OTV6I4Z0 Limited Genetic Variation [76]
RGS13 OTPAMQ18 Disputed Altered Expression [81]
RTEL1 OTI3PJCT Disputed Altered Expression [82]
ARID1A OTRWDV3P moderate Biomarker [18]
AUTS2 OTAEXHSC moderate FusionGene [83]
CCT6B OTCJCBMA moderate Biomarker [18]
CD79A OTOJC8DV moderate Biomarker [84]
COG1 OT3JSAF7 moderate Biomarker [85]
ETV6 OTCZMG61 moderate FusionGene [86]
FTCD OTX9HZT5 moderate Biomarker [18]
HLA-C OTV38BUJ moderate SusceptibilityMutation [87]
HLF OTTRK9XN moderate FusionGene [88]
IKZF1 OTCW1FKL moderate Biomarker [89]
PC OT6O0V51 moderate Biomarker [18]
PIK3R1 OT5BZ1J9 moderate Biomarker [18]
PIP4K2A OTO9JO9U moderate SusceptibilityMutation [17]
SALL3 OTJ2LZKQ moderate Biomarker [18]
A4GALT OTPX3UGY Strong Biomarker [90]
ADGRE2 OTUYJVYG Strong Altered Expression [91]
ADGRE5 OTTSB84Q Strong Biomarker [91]
APOBEC3C OTPL0AI1 Strong Genetic Variation [92]
ARHGAP24 OTCQCEZS Strong Biomarker [93]
ASPG OT5E2EKR Strong Biomarker [94]
ATP2A3 OTFYDEES Strong Altered Expression [95]
BCL7A OTYFUJTP Strong Genetic Variation [96]
BCL9 OTRBIPR4 Strong Genetic Variation [97]
BRD8 OTIKS3PC Strong Biomarker [50]
C11orf58 OTUHIICR Strong Biomarker [50]
C4A OTXMOYXU Strong Biomarker [98]
CAMK1 OTRN55RE Strong Biomarker [48]
CD81 OTQFXNAZ Strong Altered Expression [37]
CDCA7 OT12HDZY Strong Altered Expression [99]
CDCA7L OT1FFWKC Strong Biomarker [100]
CENPC OTVJ6VE9 Strong Genetic Variation [101]
CHAC1 OTJGE772 Strong Biomarker [102]
CHGB OT7SAQT2 Strong Altered Expression [31]
CKS1B OTNUPLUJ Strong Altered Expression [103]
CLEC4D OTT7X1UC Strong Biomarker [40]
DAP3 OTNPEZYM Strong Altered Expression [77]
DCLRE1C OTW3KB1I Strong Biomarker [104]
DDT OTF5HTYL Strong Genetic Variation [101]
DLEC1 OTMKKBUW Strong Altered Expression [105]
DOK1 OTGVRLW6 Strong Posttranslational Modification [106]
DUSP16 OTK7S078 Strong Posttranslational Modification [107]
E2F4 OTB3JFH4 Strong Biomarker [108]
E2F8 OTQKZGFP Strong Biomarker [109]
EPS8 OTZ6ES6V Strong Altered Expression [110]
FANCB OTMZTXB5 Strong Genetic Variation [111]
FANCM OTNJG99Z Strong Genetic Variation [112]
FAU OTGTVOWK Strong Biomarker [113]
FH OTEQWU6Q Strong Biomarker [40]
GCSAM OTZNOPYK Strong Biomarker [114]
GNA13 OTVDL515 Strong Biomarker [74]
HACE1 OTEZULKD Strong Altered Expression [115]
HELLS OTVVV668 Strong Biomarker [116]
HERPUD1 OT9EROL6 Strong Genetic Variation [101]
ID3 OTUULW5Z Strong Altered Expression [117]
ID4 OTPMJ39I Strong Biomarker [118]
IRF4 OT1DHQ1P Strong Biomarker [119]
KAT2A OTN0W2SW Strong Altered Expression [120]
KIFAP3 OT450PAO Strong Biomarker [50]
KRT20 OT4RB40L Strong Altered Expression [51]
LEF1 OTWS5I5H Strong Biomarker [121]
LGALS4 OTKQCG0H Strong Altered Expression [122]
LMO4 OT5NDCT9 Strong Altered Expression [123]
MAX OTKZ0YKM Strong Altered Expression [124]
MICA OTPEIEAR Strong Altered Expression [125]
MLLT11 OTG5RVHC Strong Altered Expression [126]
MRGPRF OT74OZ2Z Strong Biomarker [119]
NAB2 OTG4BDF3 Strong Biomarker [127]
NBAS OTW9IBRI Strong Altered Expression [53]
NLK OT2LETFS Strong Altered Expression [128]
NOL3 OT1K0L0D Strong Biomarker [129]
NOP56 OTT67SRZ Strong Biomarker [130]
NPC1 OTRIPICX Strong Genetic Variation [131]
OPN1MW OTPJ7LX4 Strong Biomarker [126]
PBX1 OTORABGO Strong Biomarker [132]
PCBP1 OTHN0TD7 Strong Genetic Variation [133]
PIGA OT51UWUR Strong Genetic Variation [134]
PIK3AP1 OTMW1B47 Strong Altered Expression [135]
PLCG2 OTGVC9MY Strong Biomarker [136]
PLIN2 OTRXJ9UN Strong Biomarker [137]
PLK3 OT19CT2Z Strong Altered Expression [58]
PMAIP1 OTXEE550 Strong Biomarker [138]
POLI OTBA4DCE Strong Altered Expression [139]
POLM OT0SRIP4 Strong Altered Expression [140]
POU2F2 OTPV0J0C Strong Altered Expression [141]
PSMA6 OTJ6RPX5 Strong Genetic Variation [142]
PWWP3A OTXQVL4U Strong Genetic Variation [143]
QPCTL OTJD4K8A Strong Biomarker [144]
RAB11A OTC4FW0J Strong Biomarker [145]
RANGAP1 OTZGD3LJ Strong Altered Expression [146]
RBFOX2 OTXY1WVH Strong Biomarker [119]
RBL2 OTBQSOE6 Strong Altered Expression [147]
RERE OT3G4GBZ Strong Altered Expression [19]
RPN1 OTEG4KU9 Strong Altered Expression [148]
RTL10 OTHGB81W Strong Biomarker [149]
SCN7A OTK05PXY Strong Altered Expression [53]
SEC14L3 OTGQ8GWM Strong Biomarker [150]
SH2D1A OTLU49I5 Strong Genetic Variation [151]
SIRT4 OT5S0J23 Strong Biomarker [152]
SMARCA1 OT0Y6PTU Strong Biomarker [64]
SMC3 OTWGFRHD Strong Altered Expression [153]
SMR3A OT6NAJJI Strong Genetic Variation [92]
SOX11 OT4LG7LA Strong Altered Expression [154]
SPAG9 OT45AHMB Strong Biomarker [155]
SRM OT4N5MDP Strong Biomarker [156]
TCF7L1 OTTUTF0O Strong Biomarker [60]
TCL1B OT4CSO39 Strong Altered Expression [34]
TFAP4 OT1KQIUX Strong Altered Expression [128]
TFE3 OTM99ZWH Strong Altered Expression [157]
TNFSF8 OTDYGDJ3 Strong Altered Expression [158]
MIXL1 OT584VOQ Definitive Altered Expression [159]
RGS1 OTGXJYMG Definitive Altered Expression [81]
SERPINA9 OT0OIZH1 Definitive Altered Expression [160]
------------------------------------------------------------------------------------
⏷ Show the Full List of 120 DOT(s)

References

1 Dexamethasone FDA Label
2 Doxorubicin FDA Label
3 Methotrexate FDA Label
4 Vincristine FDA Label
5 Point mutations in the c-Myc transactivation domain are common in Burkitt's lymphoma and mouse plasmacytomas. Nat Genet. 1993 Sep;5(1):56-61. doi: 10.1038/ng0993-56.
6 HIV Tat induces a prolonged MYC relocalization next to IGH in circulating B-cells.Leukemia. 2017 Nov;31(11):2515-2522. doi: 10.1038/leu.2017.106. Epub 2017 Mar 31.
7 High expression of apoptosis-regulating proteins in Burkitt's lymphomas.Haematologica. 2002 Mar;87(3):ELT16.
8 A combination of LMO2 negative and CD38 positive is useful for the diagnosis of Burkitt lymphoma.Diagn Pathol. 2019 Sep 4;14(1):100. doi: 10.1186/s13000-019-0876-3.
9 Cancer biomarkers in HIV patients.Curr Opin HIV AIDS. 2010 Nov;5(6):531-7. doi: 10.1097/COH.0b013e32833f327e.
10 The in vivo role of the RP-Mdm2-p53 pathway in signaling oncogenic stress induced by pRb inactivation and Ras overexpression.PLoS One. 2011;6(6):e21625. doi: 10.1371/journal.pone.0021625. Epub 2011 Jun 29.
11 Therapy-related acute myeloid leukemia with eosinophilia, basophilia, t(4;14)(q12;q24) and PDGFRA rearrangement: a case report and review of the literature.Int J Clin Exp Pathol. 2015 May 1;8(5):5812-20. eCollection 2015.
12 BRG1 regulation by miR-155 in human leukemia and lymphoma cell lines.Clin Transl Oncol. 2017 Aug;19(8):1010-1017. doi: 10.1007/s12094-017-1633-2. Epub 2017 Mar 1.
13 Emergency or urgent splenectomy in children for non-traumatic reasons.Eur J Pediatr. 2019 Sep;178(9):1363-1367. doi: 10.1007/s00431-019-03424-6. Epub 2019 Jul 16.
14 Interaction kinetics with transcriptomic and secretory responses of CD19-CAR natural killer-cell therapy in CD20 resistant non-hodgkin lymphoma.Leukemia. 2020 May;34(5):1291-1304. doi: 10.1038/s41375-019-0663-x. Epub 2019 Nov 26.
15 Detection of FLT3 gene and FLT3/ITD mutation by polymerase chain reaction-single-strand conformation polymorphism in patients with acute lymphoblastic leukemia.Di Yi Jun Yi Da Xue Xue Bao. 2005 Oct;25(10):1207-10.
16 FOXP1 and PAX5 are rare but recurrent translocations partners in acute lymphoblastic leukemia.Cancer Genet. 2011 Aug;204(8):462-4. doi: 10.1016/j.cancergen.2011.07.006.
17 Variation at 10p12.2 and 10p14 influences risk of childhood B-cell acute lymphoblastic leukemia and phenotype.Blood. 2013 Nov 7;122(19):3298-307. doi: 10.1182/blood-2013-03-491316. Epub 2013 Aug 30.
18 The genetic landscape of mutations in Burkitt lymphoma.Nat Genet. 2012 Dec;44(12):1321-5. doi: 10.1038/ng.2468. Epub 2012 Nov 11.
19 Evaluation of ARG protein expression in mature B cell lymphomas compared to non-neoplastic reactive lymph node.Cell Immunol. 2009;259(2):111-6. doi: 10.1016/j.cellimm.2009.06.004. Epub 2009 Jun 6.
20 Deficiency of the proapoptotic SAP function in X-linked lymphoproliferative disease aggravates Epstein-Barr virus (EBV) induced mononucleosis and promotes lymphoma development.Immunol Lett. 2010 May 4;130(1-2):13-8. doi: 10.1016/j.imlet.2010.01.002. Epub 2010 Jan 18.
21 -elemene against Burkitt's lymphoma via activation of PUMA mediated apoptotic pathway.Biomed Pharmacother. 2018 Oct;106:1557-1562. doi: 10.1016/j.biopha.2018.07.124. Epub 2018 Jul 26.
22 BCL-W has a fundamental role in B cell survival and lymphomagenesis.J Clin Invest. 2017 Feb 1;127(2):635-650. doi: 10.1172/JCI89486. Epub 2017 Jan 17.
23 Abemaciclib, a CDK4/6 inhibitor, exerts preclinical activity against aggressive germinal center-derived B-cell lymphomas.Cancer Sci. 2020 Feb;111(2):749-759. doi: 10.1111/cas.14286. Epub 2020 Jan 13.
24 Immunophenotypic and genotypic analysis of acquired immunodeficiency syndrome-related non-Hodgkin's lymphomas. Correlation with histologic features in 36 cases. French Study Group of Pathology for HIV-Associated Tumors.Am J Clin Pathol. 1994 Jun;101(6):773-82. doi: 10.1093/ajcp/101.6.773.
25 LMP1-deficient Epstein-Barr virus mutant requires T cells for lymphomagenesis.J Clin Invest. 2015 Jan;125(1):304-15. doi: 10.1172/JCI76357. Epub 2014 Dec 8.
26 Myc translocations in B cell and plasma cell neoplasms.DNA Repair (Amst). 2006 Sep 8;5(9-10):1213-24. doi: 10.1016/j.dnarep.2006.05.017. Epub 2006 Jul 11.
27 Recurrent deletions of the TNFSF7 and TNFSF9 genes in 19p13.3 in diffuse large B-cell and Burkitt lymphomas.Int J Cancer. 2012 Sep 1;131(5):E830-5. doi: 10.1002/ijc.27416. Epub 2012 Jan 31.
28 Continuous signaling of CD79b and CD19 is required for the fitness of Burkitt lymphoma B cells.EMBO J. 2018 Jun 1;37(11):e97980. doi: 10.15252/embj.201797980. Epub 2018 Apr 18.
29 A modified version of galectin-9 induces cell cycle arrest and apoptosis of Burkitt and Hodgkin lymphoma cells.Br J Haematol. 2008 Aug;142(4):583-94. doi: 10.1111/j.1365-2141.2008.07229.x. Epub 2008 May 22.
30 Adult high-grade B-cell lymphoma with Burkitt lymphoma signature: genomic features and potential therapeutic targets.Blood. 2017 Oct 19;130(16):1819-1831. doi: 10.1182/blood-2017-02-767335. Epub 2017 Aug 11.
31 Dysregulated expressions of PTEN, NF-B, WWP2, p53 and c-Myc in different subtypes of B cell lymphoma and reactive follicular hyperplasia.Am J Transl Res. 2019 Feb 15;11(2):1092-1101. eCollection 2019.
32 Efficient EBV superinfection of group I Burkitt's lymphoma cells distinguishes requirements for expression of the Cp viral promoter and can activate the EBV productive cycle.Virology. 1995 Feb 1;206(2):866-77. doi: 10.1006/viro.1995.1009.
33 Absence of G-CSF receptors and absent response to G-CSF in childhood Burkitt's lymphoma and B-ALL cells.Br J Haematol. 1995 Apr;89(4):771-9. doi: 10.1111/j.1365-2141.1995.tb08414.x.
34 MiR-29 silencing modulates the expression of target genes related to proliferation, apoptosis and methylation in Burkitt lymphoma cells.J Cancer Res Clin Oncol. 2018 Mar;144(3):483-497. doi: 10.1007/s00432-017-2575-3. Epub 2018 Jan 9.
35 Analysis of variable region genes encoding a human anti-DNA antibody of normal origin. Implications for the molecular basis of human autoimmune responses.J Immunol. 1989 Jul 15;143(2):685-91.
36 Glucocorticoids activate Epstein Barr virus lytic replication through the upregulation of immediate early BZLF1 gene expression.Brain Behav Immun. 2010 Oct;24(7):1089-96. doi: 10.1016/j.bbi.2010.04.013. Epub 2010 May 11.
37 The importance of CD39, CD43, CD81, and CD95 expression for differentiating B cell lymphoma by flow cytometry.Cytometry B Clin Cytom. 2018 May;94(3):451-458. doi: 10.1002/cyto.b.21533. Epub 2017 May 24.
38 Differential effect of IL-4 and IL-13 on CD44 expression in the Burkitt's lymphoma B cell line BL30/B95-8 and in Epstein-Barr virus (EBV) transformed human B cells: loss of IL-13 receptors on Burkitt's lymphoma B cells.Cell Immunol. 2001 Aug 1;211(2):131-42. doi: 10.1006/cimm.2001.1829.
39 S-Geranylgeranyl-L-glutathione is a ligand for human B cell-confinement receptor P2RY8.Nature. 2019 Mar;567(7747):244-248. doi: 10.1038/s41586-019-1003-z. Epub 2019 Mar 6.
40 DNA replication licensing in peripheral B-cell lymphoma.J Pathol. 2005 Feb;205(3):318-28. doi: 10.1002/path.1695.
41 The transcriptional repressor HDAC7 promotes apoptosis and c-Myc downregulation in particular types of leukemia and lymphoma.Cell Death Dis. 2015 Feb 12;6(2):e1635. doi: 10.1038/cddis.2014.594.
42 Formation of human IFN-beta complex with the soluble type I interferon receptor IFNAR-2 leads to enhanced IFN stability, pharmacokinetics, and antitumor activity in xenografted SCID mice.J Interferon Cytokine Res. 2004 Feb;24(2):119-29. doi: 10.1089/107999004322813363.
43 The interleukin-12 and interleukin-12 receptor system in normal and transformed human B lymphocytes.Haematologica. 2002 Apr;87(4):434-42.
44 Heterogeneous expression of interleukin-18 and its receptor in B-cell lymphoproliferative disorders deriving from naive, germinal center, and memory B lymphocytes.Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):144-54. doi: 10.1158/1078-0432.ccr-1026-3.
45 Adhesion molecule CD11a/CD18-deficient Burkitt's lymphoma cells lack the transcript for the beta, but not the alpha, integrin subunit.Eur J Haematol. 1997 Jan;58(1):32-9. doi: 10.1111/j.1600-0609.1997.tb01407.x.
46 The accuracy of diagnosing Burkitt lymphoma in serous effusion specimen: A cytological-histological correlation with ancillary studies.Cytopathology. 2019 Jul;30(4):378-384. doi: 10.1111/cyt.12707. Epub 2019 May 6.
47 CD95-mediated apoptosis in Burkitt's lymphoma B-cells is associated with Pim-1 down-regulation.Biochim Biophys Acta Mol Basis Dis. 2017 Jan;1863(1):239-252. doi: 10.1016/j.bbadis.2016.09.012. Epub 2016 Sep 15.
48 Comparison of gene expression profiles of lymphoma cell lines from transformed follicular lymphoma, Burkitt's lymphoma and de novo diffuse large B-cell lymphoma.Cancer Sci. 2003 Sep;94(9):774-81. doi: 10.1111/j.1349-7006.2003.tb01518.x.
49 The Epstein-Barr virus latent membrane protein 1 induces interleukin-10 in Burkitt's lymphoma cells but not in Hodgkin's cells involving the p38/SAPK2 pathway.Virology. 2001 Feb 15;280(2):183-98. doi: 10.1006/viro.2000.0768.
50 Protein phosphatase 2A activation as a therapeutic strategy for managing MYC-driven cancers.J Biol Chem. 2020 Jan 17;295(3):757-770. doi: 10.1074/jbc.RA119.011443. Epub 2019 Dec 10.
51 Anti-human SIRP antibody is a new tool for cancer immunotherapy.Cancer Sci. 2018 May;109(5):1300-1308. doi: 10.1111/cas.13548. Epub 2018 Apr 15.
52 Expression of platelet parameters and platelet membrane glycoproteins in childhood Burkitt lymphoma.Leuk Res. 2019 Sep;84:106189. doi: 10.1016/j.leukres.2019.106189. Epub 2019 Jul 12.
53 Expression of a particular beta-N-acetylglucosaminidase isoenzyme in human haematopoietic leukemic cell-lines.Cell Biochem Funct. 1986 Jul;4(3):197-203. doi: 10.1002/cbf.290040306.
54 ARK5 is transcriptionally regulated by the Large-MAF family and mediates IGF-1-induced cell invasion in multiple myeloma: ARK5 as a new molecular determinant of malignant multiple myeloma.Oncogene. 2005 Oct 20;24(46):6936-44. doi: 10.1038/sj.onc.1208844.
55 MDM4 Is Targeted by 1q Gain and Drives Disease in Burkitt Lymphoma.Cancer Res. 2019 Jun 15;79(12):3125-3138. doi: 10.1158/0008-5472.CAN-18-3438. Epub 2019 Apr 18.
56 The direct Myc target Pim3 cooperates with other Pim kinases in supporting viability of Myc-induced B-cell lymphomas.Oncotarget. 2011 Jun;2(6):448-60. doi: 10.18632/oncotarget.283.
57 Selective killing of Burkitt's lymphoma cells by mBAFF-targeted delivery of PinX1.Leukemia. 2011 Feb;25(2):331-40. doi: 10.1038/leu.2010.261. Epub 2010 Nov 19.
58 Transcriptional silencing of Polo-like kinase 2 (SNK/PLK2) is a frequent event in B-cell malignancies.Blood. 2006 Jan 1;107(1):250-6. doi: 10.1182/blood-2005-03-1194. Epub 2005 Sep 13.
59 Immunoglobulin delta expression in Burkitt's lymphoma cell lines.J Natl Cancer Inst. 1989 Jul 19;81(14):1075-9. doi: 10.1093/jnci/81.14.1075.
60 Oncogenic mechanisms in Burkitt lymphoma.Cold Spring Harb Perspect Med. 2014 Feb 1;4(2):a014282. doi: 10.1101/cshperspect.a014282.
61 Addiction to Runx1 is partially attenuated by loss of p53 in the E-Myc lymphoma model.Oncotarget. 2016 Apr 26;7(17):22973-87. doi: 10.18632/oncotarget.8554.
62 Down-regulation of SENP1 expression increases apoptosis of Burkitt lymphoma cells.Asian Pac J Cancer Prev. 2012;13(5):2045-9. doi: 10.7314/apjcp.2012.13.5.2045.
63 SYK Inhibition Induces Apoptosis in Germinal Center-Like B Cells by Modulating the Antiapoptotic Protein Myeloid Cell Leukemia-1, Affecting B-Cell Activation and Antibody Production.Front Immunol. 2018 Apr 24;9:787. doi: 10.3389/fimmu.2018.00787. eCollection 2018.
64 The mutational landscape of Burkitt-like lymphoma with 11q aberration is distinct from that of Burkitt lymphoma.Blood. 2019 Feb 28;133(9):962-966. doi: 10.1182/blood-2018-07-864025. Epub 2018 Dec 19.
65 CD30 ligand, a member of the TNF ligand superfamily, with growth and activation control CD30+ lymphoid and lymphoma cells.Leuk Lymphoma. 1996 Feb;20(5-6):397-409. doi: 10.3109/10428199609052421.
66 Enhanced apoptotic cell clearance capacity and B cell survival factor production by IL-10-activated macrophages: implications for Burkitt's lymphoma.J Immunol. 2005 Mar 1;174(5):3015-23. doi: 10.4049/jimmunol.174.5.3015.
67 Mitotic infidelity and centrosome duplication errors in cells overexpressing tripeptidyl-peptidase II.Cancer Res. 2005 Feb 15;65(4):1361-8. doi: 10.1158/0008-5472.CAN-04-2085.
68 Expression of a new isoform of the tumor susceptibility TSG101 protein lacking a leucine zipper domain in Burkitt lymphoma cell lines.Oncogene. 1999 Apr 1;18(13):2253-9. doi: 10.1038/sj.onc.1202551.
69 A human Burkitt's lymphoma cell line carrying t(8;22) and t(14;18) translocations.Ann Hematol. 2007 Nov;86(11):821-30. doi: 10.1007/s00277-007-0313-7. Epub 2007 Jul 11.
70 Interaction of the oncoprotein transcription factor MYC with its chromatin cofactor WDR5 is essential for tumor maintenance.Proc Natl Acad Sci U S A. 2019 Dec 10;116(50):25260-25268. doi: 10.1073/pnas.1910391116. Epub 2019 Nov 25.
71 ZAP-70 expression in normal pro/pre B cells, mature B cells, and in B-cell acute lymphoblastic leukemia.Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):726-34. doi: 10.1158/1078-0432.CCR-05-1531.
72 Detection of Chromosomal Translocation in Hematologic Malignancies by a Novel DNA-Based Looped Ligation Assay (LOLA).Clin Chem. 2017 Jul;63(7):1278-1287. doi: 10.1373/clinchem.2016.270140. Epub 2017 May 17.
73 Therapy-related acute lymphoblastic leukemia with MLL rearrangement following treatment of Burkitt's leukemia.Leuk Lymphoma. 2005 Jun;46(6):925-7. doi: 10.1080/10428190500052248.
74 Inactivating mutations in GNA13 and RHOA in Burkitt's lymphoma and diffuse large B-cell lymphoma: a tumor suppressor function for the G13/RhoA axis in B cells.Oncogene. 2016 Jul 21;35(29):3771-80. doi: 10.1038/onc.2015.442. Epub 2015 Nov 30.
75 Alternative splicing of the p53 tumor suppressor gene in the Molt-4 T-lymphoblastic leukemia cell line.Cancer Lett. 1993 Sep 30;73(2-3):141-8. doi: 10.1016/0304-3835(93)90256-9.
76 Biallelic deletion and loss of expression analysis of genes at FRA2G common fragile site in tumor-derived cell lines.Cancer Genet Cytogenet. 2005 Sep;161(2):181-6. doi: 10.1016/j.cancergencyto.2005.01.018.
77 Tiling resolution array comparative genomic hybridization, expression and methylation analyses of dup(1q) in Burkitt lymphomas and pediatric high hyperdiploid acute lymphoblastic leukemias reveal clustered near-centromeric breakpoints and overexpression of genes in 1q22-32.3.Hum Mol Genet. 2007 Sep 15;16(18):2215-25. doi: 10.1093/hmg/ddm173. Epub 2007 Jul 5.
78 Histone deacetylase inhibitor potentiates chemotherapy-induced apoptosis through Bim upregulation in Burkitt's lymphoma cells.J Cancer Res Clin Oncol. 2012 Feb;138(2):317-25. doi: 10.1007/s00432-011-1093-y. Epub 2011 Dec 1.
79 Immunoglobulin superfamily receptor translocation associated 2 protein on lymphoma cell lines and hairy cell leukemia cells detected by novel monoclonal antibodies.Clin Cancer Res. 2005 Jan 1;11(1):87-96.
80 NATH, a novel gene overexpressed in papillary thyroid carcinomas.Oncogene. 2002 Aug 1;21(33):5056-68. doi: 10.1038/sj.onc.1205687.
81 RGS1 and RGS13 mRNA silencing in a human B lymphoma line enhances responsiveness to chemoattractants and impairs desensitization.J Leukoc Biol. 2006 Jun;79(6):1357-68. doi: 10.1189/jlb.1105693. Epub 2006 Mar 24.
82 Pre-clinical pharmacology of AZD3965, a selective inhibitor of MCT1: DLBCL, NHL and Burkitt's lymphoma anti-tumor activity.Oncotarget. 2017 May 25;8(41):69219-69236. doi: 10.18632/oncotarget.18215. eCollection 2017 Sep 19.
83 PAX5-AUTS2: a recurrent fusion gene in childhood B-cell precursor acute lymphoblastic leukemia.Leuk Res. 2012 Aug;36(8):e178-81. doi: 10.1016/j.leukres.2012.04.015. Epub 2012 May 12.
84 Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma.Nature. 2010 Jan 7;463(7277):88-92. doi: 10.1038/nature08638.
85 Identification of novel fusion genes with 28S ribosomal DNA in hematologic malignancies.Int J Oncol. 2014 Apr;44(4):1193-8. doi: 10.3892/ijo.2014.2291. Epub 2014 Feb 5.
86 Simultaneous occurrence of ETV6-RUNX1 and BCR-ABL1 (e1a2) transcripts in a child with B-cell acute lymphoblastic leukemia.Cancer Genet. 2013 Mar;206(3):97-101. doi: 10.1016/j.cancergen.2013.01.004. Epub 2013 Mar 13.
87 KIR ligand C2 is associated with increased susceptibility to childhood ALL and confers an elevated risk for late relapse.Blood. 2014 Oct 2;124(14):2248-51. doi: 10.1182/blood-2014-05-572065. Epub 2014 Aug 27.
88 Aberrant induction of LMO2 by the E2A-HLF chimeric transcription factor and its implication in leukemogenesis of B-precursor ALL with t(17;19).Blood. 2010 Aug 12;116(6):962-70. doi: 10.1182/blood-2009-09-244673. Epub 2010 Jun 2.
89 High frequency of IKZF1 genetic alterations in adult patients with B-cell acute lymphoblastic leukemia.Eur J Haematol. 2013 Sep;91(3):201-208. doi: 10.1111/ejh.12155. Epub 2013 Jul 7.
90 Flavopiridol induces apoptosis and caspase-3 activation of a newly characterized Burkitt's lymphoma cell line containing mutant p53 genes. Blood Cells Mol Dis. 2001 May-Jun;27(3):610-24. doi: 10.1006/bcmd.2001.0428.
91 Identification of ADGRE5 as discriminating MYC target between Burkitt lymphoma and diffuse large B-cell lymphoma.BMC Cancer. 2019 Apr 5;19(1):322. doi: 10.1186/s12885-019-5537-0.
92 Percutaneous interventional management of biliary complications after pediatric liver transplantation: A 16-year single-institution experience.Pediatr Transplant. 2017 Feb;21(1). doi: 10.1111/petr.12837. Epub 2016 Oct 30.
93 Methylation-independent silencing of the p73 gene in neuroblastoma.Oncogene. 2000 Sep 14;19(39):4553-6. doi: 10.1038/sj.onc.1203807.
94 Mechanisms of cell death induced by arginase and asparaginase in precursor B-cell lymphoblasts.Apoptosis. 2019 Feb;24(1-2):145-156. doi: 10.1007/s10495-018-1506-3.
95 Modulation of B-cell endoplasmic reticulum calcium homeostasis by Epstein-Barr virus latent membrane protein-1.Mol Cancer. 2009 Aug 3;8:59. doi: 10.1186/1476-4598-8-59.
96 The whole-genome landscape of Burkitt lymphoma subtypes.Blood. 2019 Nov 7;134(19):1598-1607. doi: 10.1182/blood.2019001880.
97 Structural genome variations in individuals with childhood cancer and tumour predisposition syndromes.Eur J Cancer. 2013 Jun;49(9):2170-8. doi: 10.1016/j.ejca.2013.02.002. Epub 2013 Mar 6.
98 The 5' regulatory sequences of active miR-146a promoters are hypomethylated and associated with euchromatic histone modification marks in B lymphoid cells.Biochem Biophys Res Commun. 2013 Apr 19;433(4):489-95. doi: 10.1016/j.bbrc.2013.03.022. Epub 2013 Mar 23.
99 CDCA7 is a critical mediator of lymphomagenesis that selectively regulates anchorage-independent growth.Haematologica. 2018 Oct;103(10):1669-1678. doi: 10.3324/haematol.2018.188961. Epub 2018 Jun 7.
100 Regulation of c-fgr proto-oncogene expression in Epstein-Barr virus infected B-cell lines.Int J Cancer. 1990 Feb 15;45(2):342-6. doi: 10.1002/ijc.2910450222.
101 Multiprotein complexes present at the MIF motifs flanking the promoter of the human c-myc gene.FEBS Lett. 2000 May 26;474(1):23-8. doi: 10.1016/s0014-5793(00)01562-3.
102 Artesunate activates the ATF4-CHOP-CHAC1 pathway and affects ferroptosis in Burkitt's Lymphoma.Biochem Biophys Res Commun. 2019 Nov 12;519(3):533-539. doi: 10.1016/j.bbrc.2019.09.023. Epub 2019 Sep 16.
103 Myc targets Cks1 to provoke the suppression of p27Kip1, proliferation and lymphomagenesis.EMBO J. 2007 May 16;26(10):2562-74. doi: 10.1038/sj.emboj.7601691. Epub 2007 Apr 26.
104 PNAEmu can significantly reduce Burkitt's lymphoma tumor burden in a SCID mice model: cells dissemination similar to the human disease.Cancer Gene Ther. 2009 Oct;16(10):786-93. doi: 10.1038/cgt.2009.26. Epub 2009 Apr 10.
105 DLC-1 as a modulator of proliferation, apoptosis and migration in Burkitt's lymphoma cells.Mol Biol Rep. 2011 Mar;38(3):1915-20. doi: 10.1007/s11033-010-0311-z. Epub 2010 Oct 1.
106 Inactivation of the putative suppressor gene DOK1 by promoter hypermethylation in primary human cancers.Int J Cancer. 2012 Jun 1;130(11):2484-94. doi: 10.1002/ijc.26299. Epub 2011 Sep 22.
107 DUSP16 is an epigenetically regulated determinant of JNK signalling in Burkitt's lymphoma.Br J Cancer. 2010 Jul 13;103(2):265-74. doi: 10.1038/sj.bjc.6605711. Epub 2010 Jun 15.
108 Burkitt lymphoma-associated network construction and important network motif analysis.Oncol Lett. 2018 Sep;16(3):3054-3062. doi: 10.3892/ol.2018.9010. Epub 2018 Jun 21.
109 Integrated analysis of 10 lymphoma datasets identifies E2F8 as a key regulator in Burkitt's lymphoma and mantle cell lymphoma.Am J Transl Res. 2019 Jul 15;11(7):4382-4396. eCollection 2019.
110 Effect of trichostatin A on Burkitt's lymphoma cells: Inhibition of EPS8 activity through Phospho-Erk1/2 pathway.Biochem Biophys Res Commun. 2018 Mar 18;497(4):990-996. doi: 10.1016/j.bbrc.2018.02.128. Epub 2018 Feb 17.
111 FAB LMB 96 Regimen for Newly Diagnosed Burkitt Lymphoma in Children: Single-center Experience.J Pediatr Hematol Oncol. 2019 Jan;41(1):e7-e11. doi: 10.1097/MPH.0000000000001270.
112 A recurrent clonally distinct Burkitt lymphoma case highlights genetic key events contributing to oncogenesis.Genes Chromosomes Cancer. 2019 Aug;58(8):595-601. doi: 10.1002/gcc.22743. Epub 2019 Mar 27.
113 A new monoclonal antibody which binds to the cytoplasm of large cell lymphomas.Hematol Oncol. 1992 Mar-Apr;10(2):95-104. doi: 10.1002/hon.2900100205.
114 Expression of the human germinal center-associated lymphoma (HGAL) protein, a new marker of germinal center B-cell derivation.Blood. 2005 May 15;105(10):3979-86. doi: 10.1182/blood-2004-08-3112. Epub 2005 Jan 27.
115 Heterogeneous epigenetic regulation of HACE1 in Burkitt- Lymphoma-derived cells.Leuk Res. 2017 Sep;60:53-57. doi: 10.1016/j.leukres.2017.06.006. Epub 2017 Jun 16.
116 Chromatin remodeling factor lymphoid-specific helicase links with Epstein-Barr virus associated the follicular germinal center B cell lymphomas.J Cancer Res Ther. 2019;15(2):350-357. doi: 10.4103/jcrt.JCRT_243_18.
117 A new diagnostic algorithm for Burkitt and diffuse large B-cell lymphomas based on the expression of CSE1L and STAT3 and on MYC rearrangement predicts outcome.Ann Oncol. 2013 Jan;24(1):193-201. doi: 10.1093/annonc/mds209. Epub 2012 Sep 11.
118 Inhibitor of DNA binding 4 functions as a tumor suppressor and is targetable by 5-aza-2'-deoxycytosine with potential therapeutic significance in Burkitt's lymphoma.Mol Med Rep. 2016 Feb;13(2):1269-74. doi: 10.3892/mmr.2015.4640. Epub 2015 Dec 4.
119 IRF4 promotes Epstein-Barr virus activation in Burkitt's lymphoma cells.J Gen Virol. 2019 May;100(5):851-862. doi: 10.1099/jgv.0.001249. Epub 2019 Mar 25.
120 GCN5 HAT inhibition reduces human Burkitt lymphoma cell survival through reduction of MYC target gene expression and impeding BCR signaling pathways.Oncotarget. 2019 Oct 8;10(56):5847-5858. doi: 10.18632/oncotarget.27226. eCollection 2019 Oct 8.
121 Wnt signaling pathway protein LEF1 in cancer, as a biomarker for prognosis and a target for treatment.Am J Cancer Res. 2017 Jun 1;7(6):1389-1406. eCollection 2017.
122 Ongoing mutations in the N-terminal domain of c-Myc affect transactivation in Burkitt's lymphoma cell lines.Oncogene. 1994 Mar;9(3):759-63.
123 miR-150 might inhibit cell proliferation and promote cell apoptosis by targeting LMO4 in Burkitt lymphoma.J Cell Physiol. 2019 Jun;234(6):9652-9662. doi: 10.1002/jcp.27652. Epub 2018 Nov 13.
124 MicroRNA let-7a down-regulates MYC and reverts MYC-induced growth in Burkitt lymphoma cells.Cancer Res. 2007 Oct 15;67(20):9762-70. doi: 10.1158/0008-5472.CAN-07-2462.
125 Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein-Barr virus latent membrane protein-1: coordinate up-regulation of peptide transporters and HLA-class I antigen expression.Eur J Immunol. 1995 May;25(5):1374-84. doi: 10.1002/eji.1830250536.
126 The evaluation of Cannabidiol's effect on the immunotherapy of Burkitt lymphoma. Biochem Biophys Res Commun. 2019 Nov 26;520(1):225-230. doi: 10.1016/j.bbrc.2019.10.001. Epub 2019 Oct 3.
127 A Burkitt lymphoma cell line with integrated Epstein-Barr virus at a stable chromosome modification site.Virology. 1993 Jul;195(1):248-51. doi: 10.1006/viro.1993.1367.
128 Integrative microRNA and mRNA deep-sequencing expression profiling in endemic Burkitt lymphoma.BMC Cancer. 2017 Nov 13;17(1):761. doi: 10.1186/s12885-017-3711-9.
129 Partial trisomy 11, dup(11)(q23q13), as a defect characterizing lymphomas with Burkitt pathomorphology without MYC gene rearrangement.Med Oncol. 2011 Dec;28(4):1589-95. doi: 10.1007/s12032-010-9614-0. Epub 2010 Jul 27.
130 Burkitt's lymphoma-associated c-Myc mutations converge on a dramatically altered target gene response and implicate Nol5a/Nop56 in oncogenesis.Oncogene. 2014 Jul 3;33(27):3519-27. doi: 10.1038/onc.2013.338. Epub 2013 Sep 9.
131 Epstein-Barr virus from Burkitt Lymphoma biopsies from Africa and South America share novel LMP-1 promoter and gene variations.Sci Rep. 2015 Nov 23;5:16706. doi: 10.1038/srep16706.
132 B-cell development fails in the absence of the Pbx1 proto-oncogene.Blood. 2007 May 15;109(10):4191-9. doi: 10.1182/blood-2006-10-054213. Epub 2007 Jan 23.
133 The PCBP1 gene encoding poly(rC) binding protein I is recurrently mutated in Burkitt lymphoma.Genes Chromosomes Cancer. 2015 Sep;54(9):555-64. doi: 10.1002/gcc.22268. Epub 2015 Jul 14.
134 Silencing of genes required for glycosylphosphatidylinositol anchor biosynthesis in Burkitt lymphoma.Exp Hematol. 2009 Apr;37(4):423-434.e2. doi: 10.1016/j.exphem.2009.01.003.
135 Proteomics and Transcriptomics of BJAB Cells Expressing the Epstein-Barr Virus Noncoding RNAs EBER1 and EBER2.PLoS One. 2015 Jun 29;10(6):e0124638. doi: 10.1371/journal.pone.0124638. eCollection 2015.
136 A comparative global phosphoproteomics analysis of obinutuzumab (GA101) versus rituximab (RTX) against RTX sensitive and resistant Burkitt lymphoma (BL) demonstrates differential phosphorylation of signaling pathway proteins after treatment.Oncotarget. 2017 Dec 9;8(69):113895-113909. doi: 10.18632/oncotarget.23040. eCollection 2017 Dec 26.
137 The alteration of lipid metabolism in Burkitt lymphoma identifies a novel marker: adipophilin.PLoS One. 2012;7(8):e44315. doi: 10.1371/journal.pone.0044315. Epub 2012 Aug 31.
138 Homozygous deletions localize novel tumor suppressor genes in B-cell lymphomas.Blood. 2007 Jan 1;109(1):271-80. doi: 10.1182/blood-2006-06-026500. Epub 2006 Sep 7.
139 Induction of somatic hypermutation in immunoglobulin genes is dependent on DNA polymerase iota.Nature. 2002 Oct 31;419(6910):944-7. doi: 10.1038/nature01117.
140 Overexpression of human DNA polymerase mu (Pol mu) in a Burkitt's lymphoma cell line affects the somatic hypermutation rate.Nucleic Acids Res. 2004 Nov 1;32(19):5861-73. doi: 10.1093/nar/gkh929. Print 2004.
141 NF-kappa B and Oct-2 synergize to activate the human 3' Igh hs4 enhancer in B cells.J Immunol. 2004 Jan 15;172(2):1054-64. doi: 10.4049/jimmunol.172.2.1054.
142 Detection of genomic aberrations in molecularly defined Burkitt's lymphoma by array-based, high resolution, single nucleotide polymorphism analysis.Haematologica. 2010 Dec;95(12):2047-55. doi: 10.3324/haematol.2010.026831. Epub 2010 Sep 7.
143 Burkitt lymphoma in Iraqi children: A distinctive form of sporadic disease with high incidence of EBV(+) cases and more frequent expression of MUM1/IRF4 protein in cases with head and neck presentation.Pediatr Blood Cancer. 2018 Dec;65(12):e27399. doi: 10.1002/pbc.27399. Epub 2018 Sep 11.
144 Demonstration that drug-targeted down-regulation of MYC in non-Hodgkins lymphoma is directly mediated through the promoter G-quadruplex.J Biol Chem. 2011 Nov 25;286(47):41018-27. doi: 10.1074/jbc.M111.274720. Epub 2011 Sep 28.
145 Epstein-Barr virus exploits host endocytic machinery for cell-to-cell viral transmission rather than a virological synapse.J Gen Virol. 2016 Nov;97(11):2989-3006. doi: 10.1099/jgv.0.000605. Epub 2016 Sep 19.
146 Ran GTPase-activating protein 1 is a therapeutic target in diffuse large B-cell lymphoma. PLoS One. 2013 Nov 6;8(11):e79863. doi: 10.1371/journal.pone.0079863. eCollection 2013.
147 Gene expression analysis uncovers similarity and differences among Burkitt lymphoma subtypes.Blood. 2011 Mar 31;117(13):3596-608. doi: 10.1182/blood-2010-08-301556. Epub 2011 Jan 18.
148 Brassinosteroid reduces ABA accumulation leading to the inhibition of ABA-induced stomatal closure.Biochem Biophys Res Commun. 2018 Sep 26;504(1):143-148. doi: 10.1016/j.bbrc.2018.08.146. Epub 2018 Aug 29.
149 TGFbeta-mediated apoptosis of Burkitt's lymphoma BL41 cells is associated with the relocation of mitochondrial BimEL.Oncogene. 2008 May 29;27(24):3446-56. doi: 10.1038/sj.onc.1211009. Epub 2008 Jan 14.
150 RelB nuclear translocation mediated by C-terminal activator regions of Epstein-Barr virus-encoded latent membrane protein 1 and its effect on antigen-presenting function in B cells.J Virol. 2002 Feb;76(4):1914-21. doi: 10.1128/jvi.76.4.1914-1921.2002.
151 Fatal Central Nervous System Lymphocytic Vasculitis after Treatment for Burkitt Lymphoma in a Patient with a SH2D1A Mutation.Pediatr Infect Dis J. 2019 Feb;38(2):e29-e31. doi: 10.1097/INF.0000000000002154.
152 SIRT4 protein suppresses tumor formation in genetic models of Myc-induced B cell lymphoma.J Biol Chem. 2014 Feb 14;289(7):4135-44. doi: 10.1074/jbc.M113.525949. Epub 2013 Dec 24.
153 Epstein-Barr virus-encoded poly(A)(-) RNA supports Burkitt's lymphoma growth through interleukin-10 induction.EMBO J. 2000 Dec 15;19(24):6742-50. doi: 10.1093/emboj/19.24.6742.
154 Clinicopathological features of aggressive B-cell lymphomas including B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell and Burkitt lymphomas: a study of 44 patients from Argentina.Ann Diagn Pathol. 2013 Jun;17(3):250-5. doi: 10.1016/j.anndiagpath.2012.11.001. Epub 2012 Dec 14.
155 Interferon-gamma gene expression in human B-cell lines: induction by interleukin-2, protein kinase C activators, and possible effect of hypomethylation on gene regulation.Blood. 1992 Aug 1;80(3):724-32.
156 Molecular signatures that can be transferred across different omics platforms.Bioinformatics. 2017 Jul 15;33(14):i333-i340. doi: 10.1093/bioinformatics/btx241.
157 Cloning of an Alpha-TFEB fusion in renal tumors harboring the t(6;11)(p21;q13) chromosome translocation.Proc Natl Acad Sci U S A. 2003 May 13;100(10):6051-6. doi: 10.1073/pnas.0931430100. Epub 2003 Apr 28.
158 Expression and regulation of CD30 ligand and CD30 in human leukemia-lymphoma cell lines.Leukemia. 1994 Dec;8(12):2083-94.
159 Differential expression of the human MIXL1 gene product in non-Hodgkin and Hodgkin lymphomas.Hum Pathol. 2007 Mar;38(3):500-7. doi: 10.1016/j.humpath.2006.09.020.
160 Gcet1 (centerin), a highly restricted marker for a subset of germinal center-derived lymphomas.Blood. 2008 Jan 1;111(1):351-8. doi: 10.1182/blood-2007-06-094151. Epub 2007 Sep 26.